rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Supernus Pharmaceuticals, Inc.

SUPN · Nasdaq

Health CarePharmaceuticalsNot moving yet

SUPN stood above a rising 150-day average in 27 of the last 52 weekly readings, and has been out of that trend for the last 23 weeks. It is 18.7% below that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 23
Industry in uptrend
31% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$19.5M
Officials’ trades on record
14
Institutions holding
304 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 27 of 52 weeks.

17 Apr – 16 Oct
26%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$17.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

14 disclosed lines: House 12, Senate 0, executive 2; 5 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k15 May 2026filed 1 Jul 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k3 Mar 2026filed 7 Apr 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k11 Dec 2025filed 12 Jan 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k9 Oct 2025filed 18 Nov 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k24 Mar 2025filed 7 Apr 2025
Josh Gottheimer House: U.S. House ClerkNJ05soldjoint$1k–$15k23 Dec 2022filed 13 Jan 2023
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k13 Nov 2020filed 15 Dec 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k17 Jul 2020filed 19 Aug 2020
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA39bought$1k–$15k1 Jun 2020filed 16 Jun 2020
Josh Gottheimer House: U.S. House ClerkNJ05bought$1k–$15k28 May 2020filed 10 Jun 2020
James B. Renacci House: U.S. House ClerkOH16sold$15k–$50k15 Dec 2017filed 21 Dec 2017

Insiders

Buy orders, 12 months0
Sale orders, 12 months13
Buyers · sellers0 · 7
WhoDidSharesTraded
Padmanabh P. BhattSr. VP of IP, CSOsold6,838at $49.5518 Mar 2026filed 18 Mar 2026
Padmanabh P. BhattSr. VP of IP, CSOsold412at $50.4818 Mar 2026filed 18 Mar 2026
Padmanabh P. BhattSr. VP of IP, CSOsold27,710at $49.9517 Mar 2026filed 18 Mar 2026
Padmanabh P. BhattSr. VP of IP, CSOsold22,290at $50.7317 Mar 2026filed 18 Mar 2026
Padmanabh P. BhattSr. VP of IP, CSOsold34,114at $50.1816 Mar 2026filed 18 Mar 2026
Padmanabh P. BhattSr. VP of IP, CSOsold15,886at $50.4916 Mar 2026filed 18 Mar 2026
Jack A. KhattarPresident, CEOsold24,138at $50.0913 Mar 2026filed 16 Mar 2026
Jack A. KhattarPresident, CEOsold10,742at $51.0013 Mar 2026filed 16 Mar 2026
Jack A. KhattarPresident, CEOsold120at $51.7513 Mar 2026filed 16 Mar 2026
Frederick M. HudsonDirectorsold5,369at $50.6112 Mar 2026filed 16 Mar 2026
William Todd HorichSVP, Commercial Operationssold4,439at $55.0010 Mar 2026filed 10 Mar 2026
Frank MottolaSVP, Chief Tech. Ops. Officersold1,623at $53.659 Mar 2026filed 10 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders304+4 on the quarter
New · exited48 · 42
Reported value$2.7B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20269,350,046$434.9M+552,792+6.3%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20263,853,212$179.2M+537,239+16.2%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20263,305,429$153.7M+66,736+2.1%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 20262,646,201$123.1M+750,854+39.6%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,516,721$117.1M+49,506+2.0%
STATE STREET CORPadded · filed 7 Aug 20262,459,828$114.4M+171,701+7.5%
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.added · filed 14 Aug 20262,378,329$110.6M+341,127+16.7%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 20262,078,090$96.7M-228,940−9.9%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 20261,570,088$73.0M-53,426−3.3%
Stephens Investment Management Group LLCadded · filed 29 Jul 20261,485,821$69.1M+134,490+10.0%
31 Mar 2023 – 30 Jun 2026
199250300Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Frank Mottola Company insiderSVP, Chief Tech. Ops. Officer · last 12 Aug 20260 · 7
Jack A. Khattar Company insiderPresident, CEO · last 12 Aug 20263 · 35
Jonathan Rubin Company insiderSVP, Chief Medical Officer · last 12 Aug 20260 · 1
Padmanabh P. Bhatt Company insiderSr. VP of IP, CSO · last 12 Aug 20260 · 41
Timothy C. Dec Company insiderSenior Vice-President & CFO · last 12 Aug 20260 · 1
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20260 · 2
Frederick M. Hudson Company insiderDirector · last 12 Mar 20261 · 5
William Todd Horich Company insiderSVP, Commercial Operations · last 10 Mar 20260 · 2
Georges Gemayel Company insiderDirector · last 6 Mar 20260 · 5
Gilbert Ray Cisneros, Jr. HouseCA31 · last 3 Mar 20266 · 1
Carrolee Barlow Company insiderDirector · last 24 Feb 20260 · 0
Charles W. Newhall III Company insiderDirector · last 24 Feb 20261 · 6

Same industry

ABBV AbbVieLeading+20%
VTRS ViatrisLeading+16%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202589.6%
Operating profit marginFY 2025 · to 31 Dec 2025-8.7%
Free cash flow marginFY 2025 · to 31 Dec 20256.4%
Return on capital employedFY 2025 · to 31 Dec 2025-5.6%
Research spendFY 2025 · to 31 Dec 202514.8%
Share count trendFY 2025 · to 24 Feb 20260.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$128.4M
Free cash flowFY 2025 · to 31 Dec 2025$46.0M

Analyst forecasts

No analyst forecasts yet.